Emcure Pharmaceuticals Q2 FY27: revenue up 24.3% to ₹2,821 Cr, net profit up 33.7% to ₹326 Cr
Results · Finvezto · 3 Nov 2026 · Emcure Pharmaceuticals (EMCURE)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 2,821 | - | +24.3% |
| Operating profit | 588 | - | +23.6% |
| Net profit | 326 | - | +33.7% |
| Operating margin | 20.8% | - | -0.1 pp |
| Net margin | 11.5% | - | +0.8 pp |
YoY is the company's own figure. QoQ shows where our quarterly series matches the filing.
Key points
- Revenue grew by 24% year-on-year to INR 2,820 crores in Q2 FY27, supported by broad-based growth across both domestic and international markets. Earnings call
- EBITDA increased 31% year-on-year to INR 575 crores, with EBITDA margin expanding by about 100 basis points to 20.4% driven by operating leverage. Earnings call
- Domestic revenue grew 12% year-on-year to INR 1,155 crores, led by strong performance in women's health, cardiometabolic, and CNS portfolios. Earnings call
What to watch
- Management on revenue growth guidance: We now expect revenue growth to exceed 20% compared to mid-teens mentioned earlier.
- Management on ebitda margin expansion: EBITDA margin improvement for the year is now expected to be at the upper end of our guidance range of 75 to 100 basis points.
Links
Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.